Target intelligence / Profile preview

Citramalyl-CoA lyase, mitochondrial (CLYBL)

Target
CLYBL
Molecular classification
Enzyme, Lyase (oxo-acid-lyase), Mitochondrial protein
01

Overview

Citramalyl-CoA lyase, mitochondrial (CLYBL) is a mitochondrial matrix enzyme that catalyzes the cleavage of citramalyl-CoA to acetyl-CoA and pyruvate, a key step in the C5-dicarboxylate catabolic pathway involved in the metabolism and detoxification of itaconate and related metabolites[1][4][5]. CLYBL activity is required for maintaining mitochondrial vitamin B12 metabolism; loss of function leads to accumulation of upstream intermediates and a mild but consistent reduction in circulating B12. The enzyme is structurally a homotrimer and binds magnesium, demonstrating additional in vitro catalytic activities such as malate synthase and malyl-CoA thioesterase, though its primary physiological function is citramalyl-CoA cleavage[1][3]. CLYBL is highly conserved and ubiquitously expressed, and its disruption does not produce overt phenotypes apart from the B12 defect[1][3]. Notes: - There is no evidence of approved or investigational drugs targeting CLYBL, and no clear role for this protein in major disease categories (such as cancer or neurodegenerative disorders) established in the literature[3]. - The enzyme is categorized as a lyase, more specifically an oxo-acid-lyase, and is distinct from citrate lyase complexes due to lack of other complex subunits in mammals[1][5]. - The gene symbol is "CLYBL," and the main standardized protein/gene name is "citramalyl-CoA lyase, mitochondrial (CLYBL)"[3][4][5].

Other names
citrate lyase beta-like proteinCLB(3S)-malyl-CoA thioesterasebeta-methylmalate synthasemalate synthasecitrate lyase subunit beta-like protein
02

Biological functions

Cleavage of citramalyl-CoA to acetyl-CoA and pyruvateRegulation of cobalamin (vitamin B12) metabolismDetoxification of itaconate (an immunometabolite)Malate synthase activity (in vitro)Beta-methylmalate synthase activity (in vitro)Protein homotrimerization
03

Disease associations

Other (possible relevance in vitamin B12 deficiency and rare neurological conditions as per gene-disease annotations, but no clear direct disease causality established to date)
04

Safety considerations

No known direct safety concerns; loss-of-function appears tolerated but results in mild vitamin B12 deficiency
05

Biomarkers

Reduced circulating vitamin B12 (as observed in CLYBL knockout individuals)

Beyond the preview

Go deeper on Citramalyl-CoA lyase, mitochondrial (CLYBL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Citramalyl-CoA lyase, mitochondrial (CLYBL).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call